Beta-adrenergic blocking drugs were thefirst agents shown in large clinical trials toimprove the outcomes of survivors of acutemyocardial infarction (MI). Lower mortalitywas observed in the group ...
Objective: To summarize key changes in the 2007 American College of Cardiology/American Heart Association (ACC/AHA) guideline recommendations for pharmacologic therapy as they relate to antiplatelets ...
The elderly account for the majority of medical spending in many countries, raising concerns about potentially unnecessary spending, especially during the final months of life. Using a well-defined ...
Despite evidence-based guidelines for the optimal treatment of patients with acute myocardial infarction (AMI), patterns of care vary considerably between different regions of the US. Stukel and ...
Patients not only have to fight their diseases but also must deal with the pain – the more severe the condition, the more painful the injections. Recently, new doors have opened to relieve patients of ...
PARSIPPANY, N.J. and INDIANAPOLIS, Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients ...
DelveInsight's, “Myocardial Infarction Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers ...
Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...
ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results